InflaRx (NASDAQ:IFRX) Short Interest Update

InflaRx (NASDAQ:IFRX) was the target of a significant increase in short interest in the month of June. As of June 15th, there was short interest totalling 92,700 shares, an increase of 233.5% from the May 31st total of 27,800 shares. Based on an average daily trading volume, of 194,800 shares, the days-to-cover ratio is currently 0.5 days.

Hedge Funds Weigh In On InflaRx

Several hedge funds have recently bought and sold shares of IFRX. Raymond James & Associates boosted its holdings in InflaRx by 7.9% during the fourth quarter. Raymond James & Associates now owns 175,279 shares of the company’s stock valued at $286,000 after acquiring an additional 12,873 shares during the period. Ikarian Capital LLC grew its holdings in InflaRx by 2.4% in the 1st quarter. Ikarian Capital LLC now owns 704,987 shares of the company’s stock valued at $1,086,000 after buying an additional 16,383 shares during the last quarter. Franklin Street Advisors Inc. NC increased its position in InflaRx by 49.9% in the 4th quarter. Franklin Street Advisors Inc. NC now owns 75,100 shares of the company’s stock worth $122,000 after buying an additional 25,000 shares during the period. Alps Advisors Inc. lifted its holdings in shares of InflaRx by 109.4% during the third quarter. Alps Advisors Inc. now owns 83,279 shares of the company’s stock worth $248,000 after buying an additional 43,501 shares during the last quarter. Finally, Raymond James Financial Services Advisors Inc. boosted its position in shares of InflaRx by 18.2% in the fourth quarter. Raymond James Financial Services Advisors Inc. now owns 317,859 shares of the company’s stock valued at $518,000 after acquiring an additional 48,944 shares during the period. 42.39% of the stock is owned by institutional investors and hedge funds.

InflaRx Stock Up 4.4 %

InflaRx stock traded up $0.07 during mid-day trading on Thursday, hitting $1.67. The company’s stock had a trading volume of 120,174 shares, compared to its average volume of 217,775. The stock has a market capitalization of $98.33 million, a P/E ratio of -2.14 and a beta of 1.20. InflaRx has a twelve month low of $1.14 and a twelve month high of $4.61. The stock’s fifty day moving average price is $1.46 and its two-hundred day moving average price is $1.55.

InflaRx (NASDAQ:IFRX) last announced its quarterly earnings results on Wednesday, May 8th. The company reported ($0.19) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.24) by $0.05. The firm had revenue of $0.04 million for the quarter, compared to analyst estimates of $1.76 million. Equities analysts expect that InflaRx will post -0.81 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a “buy” rating and issued a $8.00 price target on shares of InflaRx in a research report on Monday.

InflaRx Company Profile

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.